Hematological Toxicities of Concurrent Chemoradiotherapies in Head and Neck Cancers: Comparison Among Cisplatin, Nedaplatin, Lobaplatin, and Nimotuzumab

Hematological Toxicities of Concurrent Chemoradiotherapies in Head and Neck Cancers: Comparison Among Cisplatin, Nedaplatin, Lobaplatin, and Nimotuzumab

BackgroundCisplatin-based concurrent chemoradiotherapy is standard of care for locally advanced head and neck cancers (LAHNC). Nedaplatin, lobaplatin and nimotuzumab have shown anti-cancer effect with less gastrointestinal toxicity and nephrotoxicity. However, the profile of hematological toxicities...

Full description

Bibliographic Details
Main Authors: Qiuji Wu, Chunmei Zhu, Shuyuan Zhang, Yunfeng Zhou, Yahua Zhong
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-10-01
Series:Frontiers in Oncology
Subjects:
concurrent chemoradiotherapy
platinum
nimotuzumab
hematological toxicity
head and neck cancer
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.762366/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.762366/full

Similar Items